Trial: 202003211

A Phase II, Open Label, Two Arm Study of Therapeutic Iobenguane (131I) as single agent or in combination with Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects (OPTIMUM Trial)

Phase

II

Principal Investigator

Huang, Frederick

Disease Site

Brain and Nervous System

Learn more about this study at: clinicaltrials.gov